 Connection
Ajay Major to Treatment Outcome
This is a "connection" page, showing publications Ajay Major has written about Treatment Outcome.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.298 |
|
|
|
-
Major A, Kline J, Karrison TG, Fishkin PAS, Kimball AS, Petrich AM, Nattam S, Rao K, Sleckman BG, Cohen K, Besien KV, Rapoport AP, Smith SM. Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas. Haematologica. 2022 07 01; 107(7):1608-1618.
Score: 0.078
-
Major A, Smith SM. DA-R-EPOCH vs R-CHOP in DLBCL: How do we choose? Clin Adv Hematol Oncol. 2021 Nov; 19(11):698-709.
Score: 0.075
-
Major A, Jackson MW, Smith DE, Kamdar M, Rabinovitch R. Inferior outcomes and treatment disparities in elderly patients with classical Hodgkin lymphoma: a national cancer data base analysis. Leuk Lymphoma. 2019 05; 60(5):1234-1243.
Score: 0.061
-
Winters AC, Minhajuddin M, Stevens BM, Major A, Bosma G, Abbott D, Miltgen N, Yuan J, Treece AL, Siegele BJ, Ewalt MD, Gutman JA, Jordan CT, Pollyea DA. Multi-gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax/azacitidine. Haematologica. 2024 06 01; 109(6):1766-1778.
Score: 0.022
-
Derman BA, Cooperrider J, Rosenblatt J, Avigan DE, Rampurwala M, Barnidge D, Major A, Karrison T, Jiang K, Ramsland A, Kubicki T, Jakubowiak AJ. Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant. Blood Cancer J. 2024 05 29; 14(1):87.
Score: 0.022
-
Dytfeld D, Wr?bel T, Jamroziak K, Kubicki T, Robak P, Walter-Croneck A, Czyz J, Tyczynska A, Druzd-Sitek A, Giannopoulos K, Nowicki A, Szczepaniak T, Lojko-Dankowska A, Matuszak M, Gil L, Pula B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski L, Konska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T, Lahoud OB, Zonder JA, Griffith K, Stefka A, Major A, Derman BA, Jakubowiak AJ. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023 02; 24(2):139-150.
Score: 0.020
-
Orellana-Noia VM, Reed DR, McCook AA, Sen JM, Barlow CM, Malecek MK, Watkins M, Kahl BS, Spinner MA, Advani R, Voorhees TJ, Snow A, Grover NS, Ayers A, Romancik J, Liu Y, Huntington SF, Chavez JC, Saeed H, Lazaryan A, Raghunathan V, Spurgeon SE, Ollila TA, Del Prete C, Olszewski A, Ayers EC, Landsburg DJ, Echalier B, Lee J, Kamdar M, Caimi PF, Fu T, Liu J, David KA, Alharthy H, Law J, Karmali R, Shah H, Stephens DM, Major A, Rojek AE, Smith SM, Yellala A, Kallam A, Nakhoda S, Khan N, Sohail MA, Hill BT, Barrett-Campbell O, Lansigan F, Switchenko J, Cohen J, Portell CA. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood. 2022 01 20; 139(3):413-423.
Score: 0.019
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|